MicroRNAs as promising biomarkers and therapeutic tools in hereditary hemorrhagic telangiectasia

Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder that results in potentially fatal blood vessel abnormalities. Currently, there is no cure or universally effective treatment for the condition, which remains underfunded and underdiagnosed. MicroRNAs have emerged as new biomarkers for human diseases and hold great promise for the improved diagnosis and treatment of HHT. A recent review publication by Anthony […]

Read More…

Off-the-shelf immunotherapy could lead to more accessible cancer treatment

Off-the-shelf immunotherapy could lead to more accessible cancer treatmen

Immunotherapy is a type of cancer treatment that harnesses the immune system to destroy cancerous cells. Dr Li Zhang and colleagues at Toronto General Hospital Research Institute and the University of Toronto, are pioneering a new type of “off-the-shelf” treatment using a type of immune cell—a double negative T (DNT) cell. Dr Zhang‘s work shows that DNT cells are a […]

Read More…

Helping patients put their best foot forward

Dr Hawker researches osteoarthritis (OA) outcomes. A predominant theme of her work is the appropriate use of hip and knee joint replacement surgery for OA.

Dr Gillian Hawker of the University of Toronto is helping potential knee replacement patients to make informed decisions about their health. As an increasing number of us require joint replacement, Dr Hawker seeks to make sure that only those who are best suited will undergo surgery. By developing standardised patient assessment criteria for knee surgery, Dr Hawker is striving to […]

Read More…

Thank you for expressing interest in joining our mailing list and community. Below you can select how you’d like us to interact with you and we’ll keep you updated with our latest content.

You can change your preferences or unsubscribe by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at audience@researchoutreach.org at any time and if you have any questions about how we handle your data, please review our privacy agreement.

Would you like to learn more about our services?

We use MailChimp as our marketing automation platform. By clicking below to submit this form, you acknowledge that the information you provide will be transferred to MailChimp for processing in accordance with their Privacy Policy and Terms.

Subscribe to our FREE PUBLICATION